Author: admin

Epilepsy Pipeline Insights, Clinical Trials, Treatment Drugs, and Companies 2024

DelveInsight’s, “Epilepsy Pipeline Insight 2024” report provides comprehensive insights about 85+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our comprehensive Epilepsy Pipeline Report to stay informed about the latest advancements. Download copy now @ Epilepsy Pipeline Outlook

 

Key Takeaways from the Epilepsy Pipeline Report

  • In September 2024:- Ono Pharmaceuticals- A Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures. To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures.
  • In September 2024:- UCB Biopharma SRL- The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.
  • In September 2024:- Biohaven Therapeutics Inc.- A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy. The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
  • DelveInsight’s Epilepsy pipeline report depicts a robust space with 85+ active players working to develop 90+ pipeline therapies for Epilepsy treatment.
  • The leading Epilepsy Companies such as UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
  • Promising Epilepsy Therapies such as Lorcaserin, Cenobamate, SPN-817, EQU-001, Diazepam Nasal Spray, Brivaracetam, Cannabidiol, Lacosamide, Perampanel, and others.

 

Dive into our Epilepsy Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Epilepsy Treatment Therapies

 

Epilepsy Emerging Drugs

  • XEN1101: Xenon Pharmaceuticals

XEN1101 is a novel, small-molecule, selective Kv7.2/Kv7.3 potassium channel opener being developed for the treatment of focal epilepsy. Its mechanism of action involves positively modulating these specific voltage-gated potassium channels, which leads to increased potassium ion flow out of neurons, resulting in neuronal hyperpolarization and reduced neuronal excitability this effect helps to decrease the likelihood of seizures occurring. XEN1101 is primarily metabolized by cytochrome P450 3A4 (CYP3A4) without substantial involvement of other CYPs, and plasma levels of XEN1101 may decrease in the presence of CYP3A4 inducers. The route of administration of this drug is oral. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of epilepsy.

  • EPX-100: Epygenix Therapeutics

EPX-100 is a potential new treatment being developed by Epygenix Therapeutics for people with Dravet syndrome. Dravet syndrome is a rare and severe form of epilepsy characterized by prolonged seizures, often happening numerous times each day. It is known that the disease is caused by a mutation in the SCN1A gene, but it is not fully understood how this mutation leads to the development of seizures. EPX-100 is a repurposed antihistamine, which was used in the 1950s and 1960s to treat itchiness. The medication is thought to be able to suppress seizures through its action on the serotonin signaling pathways, a mechanism that is different from its anti-histaminic properties. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of epilepsy.

  • Darigabat: Cerevel Therapeutics

Darigabat, formerly CVL-865, is a subtype selective positive allosteric modulator that targets GABAA receptors containing α2/3/5 subunits. It is structurally differentiated from classical benzodiazepines and minimizes activity at α1-containing receptors, which is believed to help mitigate many of the adverse events associated with benzodiazepines. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of epilepsy.

  • TRV-045: Trevena

Trevena is currently developing a novel, selective sphingosine-1-phosphate subtype 1 receptor (S1P1R) modulator, TRV045, as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy. Currently, the drug is in the Phase I stage of its clinical trial for the treatment of epilepsy.

  • OV-350: Ovid Therapeutics

OV-350 is an investigational drug being developed by Ovid therapeutics. The KCC2 transporter is a neuron-specific chloride extruder that is critical for maintaining GABA’s inhibitory function in the mature brain. Deficits in KCC2 activity have been associated with epilepsy and other neuropathological disorders. OV350 directly activates KCC2, thereby restoring chloride homeostasis in neurons and subsequently reducing hyperexcitability. The drug is currently in the preclinical stage of development for the treatment of patients with Epilepsy.

 

Download the Epilepsy Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Epilepsy Clinical Trials Assessment

 

Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Epilepsy Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Dive into our detailed Epilepsy Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ Epilepsy Products, Companies, and Unmet Needs

 

Scope of the Epilepsy Pipeline Report

  • Coverage- Global
  • Epilepsy Companies- UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
  • Epilepsy Therapies- Lorcaserin, Cenobamate, SPN-817, EQU-001, Diazepam Nasal Spray, Brivaracetam, Cannabidiol, Lacosamide, Perampanel, and others.
  • Epilepsy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Epilepsy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Gain valuable insights into emerging therapies and innovations with our Epilepsy Pipeline Report @ Epilepsy Market Drivers and Barriers, Future Perspectives and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Epilepsy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Epilepsy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. ZX008 (Fenfluramine Hydrochloride): UCB
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. STK-001: Stoke Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. BMB-101: Bright Minds Biosciences
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. NT102: Neuroene Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Epilepsy Key Companies
  21. Epilepsy Key Products
  22. Epilepsy- Unmet Needs
  23. Epilepsy- Market Drivers and Barriers
  24. Epilepsy- Future Perspectives and Conclusion
  25. Epilepsy Analyst Views
  26. Epilepsy Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epilepsy Pipeline Insights, Clinical Trials, Treatment Drugs, and Companies 2024

Ascites Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Ascites Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Ascites Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Ascites Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Ascites Market by downloading the comprehensive report from DelveInsight @ Ascites Treatment Market Size

 

Key Takeaways from the Ascites Market Report

  • In September 2024:- Versantis AG- A Phase 2a, Open-label, Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of VS-01 on Top of Standard of Care (SOC), Compared to SOC Alone, in Adult Patients With Acute-on-Chronic Liver Failure (ACLF) Grades 1 and 2 and Ascites.
  • It is estimated that the Ascites treatment market will experience significant changes during the forecast period of 2024–2034, owing to the launch of new therapies that are in clinical development.
  • DelveInsight analysis indicates that in 2023, the US had approximately 153 thousand cases of Ascites due to Cirrhosis, accounting for the largest share in the 7MM.
  • DelveInsight’s analysis revealed that in Japan during 2023, there were 5,355 instances of Grade I ascites attributed to cirrhosis. Additionally, more severe cases of Grade II and III ascites were recorded at 24,394 cases each in the same year.
  • The leading Ascites Companies such as Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.
  • Promising Ascites Therapies such as Recombinant Human Serum Albumin, M701, paracentesis, OrsHSA, VS-01, Ambrisentan, Terlipressin, and others.

 

Gain a competitive edge in the Ascites Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Ascites Treatment Drugs

 

Ascites Epidemiology Segmentation in the 7MM

  • Number of Ascites Cases by Malignancies
  • Number of Ascites Cases due to Cirrhosis
  • Severity-specific Cases of Ascites due to Cirrhosis
  • Refractory Ascites Patients with Cirrhosis

 

Ascites Treatment Market Landscape

The treatment landscape of ascites due to cirrhosis include diuretics, paracentesis, insertion of a transjugular intrahepatic portosystemic shunt (TIPS), as well as managing complications to ascites such as spontaneous bacterial peritonitis (SBP). Mild and moderate ascites due to liver cirrhosis can be treated with dietary sodium restriction, treatment of the underlying disorder, fluid restriction, use of diuretics, and use of therapeutic paracentesis.

 

Discover key developments and opportunities in the Ascites Market. Click here to learn more from DelveInsight’s latest report @ Ascites Market Size

 

Ascites Drugs Market

The Ascites market for drugs targeting ascites is notably constrained. While certain treatments provide symptomatic relief, there is a significant lack of approved drugs addressing the condition’s underlying causes. This scarcity of targeted treatments reflects a major challenge in effectively managing the diverse manifestations of ascites, indicating a substantial need for innovative solutions and advancements in drug development for more comprehensive care.

 

Ascites Emerging Drugs Profile

  • OCE-205: Ocelot Bio
  • BIV201 (terlipressin): Biovie

 

Download DelveInsight’s Ascites Market report today and stay ahead in this rapidly evolving field. @ Ascites Clinical Trials

 

Scope of the Ascites Market Report

  • Coverage- 7MM
  • Ascites Companies- as Grifols Therapeutics LLC, Sanofi, Regeneron Pharmaceuticals, Sequana Medical N.V, Protgen Ltd, Healthgen Biotechnology Corp, Sichuan Clover Biopharmaceuticals Inc, Movetis, BioVie Inc., Ocelot Bio Inc, Novartis, and others.
  • Ascites Therapies- Recombinant Human Serum Albumin, M701, paracentesis, OrsHSA, VS-01, Ambrisentan, Terlipressin, and others.
  • Ascites Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Ascites Unmet Needs, KOL’s views, Analyst’s views, Ascites Market Access and Reimbursement

 

Download the report to understand which factors are driving Ascites Market Trends @ Ascites Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Ascites Market Overview at a Glance

5 Key Events

6 Epidemiology and Market Forecast Methodology

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Emerging Therapies

11 Ascites: Seven Major Market Analysis

12 Unmet Needs

13 SWOT Analysis

14 KOL Views

15 Market Access and Reimbursement

16 Appendix

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ascites Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Netherlands Data Center Colocation Market Revenue to Reach $1.22 Billion by 2029, Get Insights on 123 Existing and 13 Upcoming Colocation Data Centers in the Netherlands – Arizton

“Netherlands Data Center Colocation Market Research Report by Arizton”

 

According to Arizton’s latest research report, the Netherlands data center colocation market is growing at a CAGR of 3.54% during 2023-2029.

       

Looking for More Information? Click: https://www.arizton.com/market-reports/netherlands-data-center-colocation-market

 

Report Scope:       

Market Size – Colocation Revenue (2029): USD 1.22 Billion  

CAGR (2023-2029): 3.54% 

Market Size – Utilized White Floor Area (2029): 6,328.6 Thousand Sq. ft  

Market Size – Utilized Racks (2029): 212.3 Thousand Units  

Market Size – Utilized IT Power Capacity (2029): 1,170 MW  

Base Year: 2023 

Forecast Year: 2024-2029 

      

Book the Free Sample Now: https://www.arizton.com/market-reports/netherlands-data-center-colocation-market

 

The Netherlands boasts a well-established colocation market, featuring approximately 123 data centers throughout the country, with a significant concentration in Amsterdam. Key players in this space include Equinix, Digital Realty, Switch Datacenters, CyrusOne, QTS Realty Trust, NTT DATA, and Iron Mountain. New entrants like Yondr, CloudHQ, and Great Grey Investments are also looking to make their mark. As of Q4 2023, Digital Realty’s occupancy rate in Amsterdam stands at about 83.2%, contributing over $175 million annually in rental income from colocation services. Retail colocation remains the dominant segment, outperforming wholesale colocation; however, demand for wholesale colocation is projected to rise due to the increasing adoption of cloud-based services. Many cloud operators are expected to utilize wholesale colocation to manage part of their workloads. Switch Datacenters is expanding its footprint in Amsterdam with two new facilities, AM-5 and AM-6, aimed at supporting the growing needs of sectors such as financial services, gaming, and aerospace. These new data centers will provide essential digital infrastructure to foster customer growth in one of the world’s fastest-growing metro areas.

 

The Growth of the Public Cloud Market and Key Developments in the Netherlands

The revenue from the Netherlands’ public cloud market is projected to exceed $11.5 billion by 2024, with a compound annual growth rate (CAGR) of over 17% anticipated from 2024 to 2029. By 2029, the market is expected to accumulate more than $25.5 billion, with the software as a service (SaaS) segment leading the way, generating over $5.5 billion in 2024.

In January 2024, QphoX, a Dutch quantum computing firm, secured $8.7 million in funding, positioning itself as one of the largest quantum companies in the country. This funding followed a $7 million grant from the European Innovation Council (EIC) Accelerator and was raised in a round led by QDNL Participations, with contributions from Quantonation, Speedinvest, EIC Fund, Delft Enterprises, and High-Tech Gründerfonds.

Significant infrastructure developments are also underway. In April 2023, Microsoft obtained final environmental permits for its data center in Hollands Kroon. In September 2023, Akamai announced plans to launch a new cloud region in Amsterdam, aiming for operations to commence by the end of the year. Additionally, in December 2023, Google began construction on a new data center in Winschoten, backed by a $655.1 million investment. These initiatives underscore the continued expansion of major tech companies like Microsoft, Google, and Akamai within the Netherlands.

 

What’s Included in the Report?

  • Transparent research methodology and insights on the market’s colocation of demand and supply.
  • The market size is available in terms of utilized white floor area, IT power capacity, and racks.
  • Market size available in terms of Core & Shell Vs Installed Vs Utilized IT Power Capacity along with the occupancy %.
  • An assessment and snapshot of the colocation investment regarding core & shell area, power, and rack in the Netherlands and a comparison between Western European countries.
  • The study of the existing Netherlands data center industry landscape and insightful predictions about industry size during the forecast period.
  • An analysis of the current and future colocation demand in the Netherlands by several industries. 
  • Study on sustainability status in the region
  • Analysis of current and future cloud operations in the region.
  • Snapshot of upcoming submarine cables and existing cloud-on-ramps services in the region.
  • Snapshot of existing and upcoming third-party data center facilities in the Netherlands
    • Facilities Covered (Existing): 123
    • Facilities Identified (Upcoming): 13
    • Coverage: 46 locations
    • Existing vs. Upcoming (White Floor Area)
    • Existing vs. Upcoming (IT Load Capacity)
    • Data Center Colocation Market in the Netherlands
      • Colocation Market Revenue & Forecast (2023-2029)
      • Retail Colocation Revenue (2023-2029)
      • Wholesale Colocation Revenue (2023-2029)
      • Retail Colocation Pricing along with Addons
      • Wholesale Colocation Pricing along with the pricing trends. 
      • An analysis of the latest trends, potential opportunities, growth restraints, and prospects for the Netherlands data center colocation market.
      • Competitive landscape, including industry share analysis by the colocation operators based on IT power capacity and revenue.
      • The vendor landscape of each existing and upcoming colocation operator is based on the existing/ upcoming count of data centers, white floor area, IT power capacity, and data center location.

 

The Report Includes:

  • Colocation Supply (MW, Area, Rack Capacity)
  • Colocation Demand (MW, Area, Rack Capacity) and by End-User (Cloud/IT, BFSI, etc)
  • Colocation Revenue (Retail & Wholesale Colocation Services)
  • Competitive Scenario (Share Analysis by Revenue & MW Capacity)

 

Vendor Landscape

Existing Operators

  • Digital Realty
  • EdgeConneX
  • NTT DATA
  • Switch Datacenters
  • CyrusOne 
  • Smartdc 
  • AtlasEdge
  • Equinix
  • atom86 
  • Bytesnet 
  • CapitaLand 
  • Cellnex
  • Colt Data Centre Services
  • Datacenter.com
  • Eurofiber Cloud Infra
  • Global Switch
  • Interconnect
  • Iron Mountain
  • Keppel Data Centres
  • NorthC
  • Previder 
  • QTS Realty Trust
  • Serverfarm 
  • Serverius
  • Other Operators

New Operators

  • cloudHQ 
  • Great Grey Investments
  • Yondr

 

In a nutshell, the Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to understand the Netherlands data center colocation market thoroughly. Request for Free Sample to get a glance at the report now: https://www.arizton.com/market-reports/netherlands-data-center-colocation-market

     

What Key Findings Will Our Research Analysis Reveal?     

What is the count of existing and upcoming colocation data center facilities in the Netherlands?

What factors are driving the Netherlands data center colocation market?

How much MW of IT power capacity is likely to be utilized in the Netherlands by 2029?

Who are the major colocation operators in the Netherlands data center industry?

     

Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4524

 

     

Other Related Reports that Might be of Your Business Requirement     

Netherlands Data Center Market – Investment Analysis & Growth Opportunities 2024-2029

https://www.arizton.com/market-reports/netherlands-data-center-market-investment-analysis

Germany Data Center Colocation Market – Supply & Demand Analysis 2024-2029

https://www.arizton.com/market-reports/germany-data-center-colocation-market

 

Why Arizton?                                                

100% Customer Satisfaction                                                

24×7 availability – we are always there when you need us                                                

200+ Fortune 500 Companies trust Arizton’s report                                                

80% of our reports are exclusive and first in the industry                                                

100% more data and analysis                                                

1500+ reports published till date                              

                   

Post-Purchase Benefit                                            

  • 1hr of free analyst discussion                                            
  • 10% off on customization                         

                  

About Us:                                                                                     

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                                   

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                                    

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                                          

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707     
Country: United States
Website: https://www.arizton.com/market-reports/netherlands-data-center-colocation-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Netherlands Data Center Colocation Market Revenue to Reach $1.22 Billion by 2029, Get Insights on 123 Existing and 13 Upcoming Colocation Data Centers in the Netherlands – Arizton

Dup15q Syndrome Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Dup15q Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Dup15q Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Dup15q Syndrome Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Dup15q Syndrome, historical and forecasted epidemiology as well as the Dup15q Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Dup15q Syndrome Market by downloading the comprehensive report from DelveInsight @ Dup15q Syndrome Treatment Market Size

 

Key Takeaways from the Dup15q Syndrome Market Report

  • It is estimated that the Dup15q Syndrome treatment market will experience significant changes during the forecast period of 2024–2034, owing to the launch of new therapiesthat are in clinical development.
  • As per DelveInsight analysis in 2023, the US reported the highest prevalent cases of Dup15q Syndrome among the 7MM, with approximately 22 thousand cases, whereas nearly 5,350 individuals accounted for diagnosed prevalent cases in the same year. DelveInsight forecasts these numbers to rise gradually throughout the 2024–2034 period.
  • According to DelveInsight’s analysis, Japan had around 402 diagnosed prevalent cases of Dup15q Syndrome in. This prevalence is further anticipated to increase gradually owing to the increase in aging population in Japan.
  • According to our secondary research, EU4 and the UK for around 15 thousand prevalent cases of Dup15q syndrome in 2023. These cases are anticipated to increase with increasing prevalence of the disease and increasing genetic mutations among individuals during the forecast period.
  • The leading Dup15q Syndrome Companies such as Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, and Zogenix, and others.
  • Promising Dup15q Syndrome Therapies such as Soticlestat, and others.

 

Gain a competitive edge in the Dup15q Syndrome Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Dup15q Syndrome Treatment Drugs

 

Dup15q Syndrome Epidemiology Segmentation in the 7MM

  • Total Dup15q Syndrome Diagnosed Prevalent Cases
  • Total Dup15q Syndrome Prevalent Cases
  • Dup15q Syndrome Type-specific Diagnosed Prevalent Cases

 

Dup15q Syndrome Market Insights

Dup15q syndrome involves hypotonia, motor delays, intellectual disability, autism spectrum disorder, and epilepsy, including infantile spasms. A comprehensive evaluation, including physical and neurological exams, EEG, and genetic consultations, is crucial for understanding individual needs. Treatment is symptom-based, with the approach tailored to the specific symptoms each patient presents.

 

Discover key developments and opportunities in the Dup15q Syndrome Market. Click here to learn more from DelveInsight’s latest report @ Dup15q Syndrome Market Size

 

Dup15q Syndrome Treatment Market

The treatment market for Dup15q syndrome remains highly limited, largely due to the rarity of the condition and the complexity of its symptoms. However, the absence of any approved therapies presents a significant opportunity for key market players to explore investments in this indication. The growing recognition of unmet medical needs in Dup15q syndrome offers a promising landscape for the development of targeted treatments, potentially driving future innovation in this area.

 

Dup15q Syndrome Emerging Drugs Profile

  • Soticlestat: Takeda Pharmaceuticals

Soticlestat, previously called TAK-935 and OV935, is an investigational treatment developed by Takeda Pharmaceuticals in collaboration with Ovid Therapeutics to treat rare developmental and epileptic encephalopathies (DEE). It is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control, and have an oral route of administration. The pipeline for Dup15q syndrome is very sparse and limited potentially indicating the limited interest of market players to invest in this disease ad simultaneously providing opportunity to the dominant player to introduce first approved therapy for Dup15q syndrome and capture a large market.

 

Download DelveInsight’s Dup15q Syndrome Market report today and stay ahead in this rapidly evolving field. @ Dup15q Syndrome Clinical Trials

 

Scope of the Dup15q Syndrome Market Report

  • Coverage- 7MM
  • Dup15q Syndrome Companies- Ovid Therapeutics, Takeda, Q-State Biosciences, Radius Health, and Zogenix, and others.
  • Dup15q Syndrome Therapies- Soticlestat, and others.
  • Dup15q Syndrome Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Dup15q Syndrome Unmet Needs, KOL’s views, Analyst’s views, Dup15q Syndrome Market Access and Reimbursement

 

Download the report to understand which factors are driving Dup15q Syndrome Market Trends @ Dup15q Syndrome Market Trends

 

Table of Content

1. Key Insights

2. Executive Summary of Dup15q Syndrome

3. Competitive Intelligence Analysis for Dup15q Syndrome

4. Dup15q Syndrome Market Overview at a Glance

5. Dup15q Syndrome: Disease Background and Overview

6. Dup15q Syndrome Patient Journey

7. Dup15q Syndrome Epidemiology and Patient Population

8. Dup15q Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Dup15q Syndrome Unmet Needs

10. Key Endpoints of Dup15q Syndrome Treatment

11. Dup15q Syndrome Marketed Products

12. Dup15q Syndrome Emerging Therapies

13. Dup15q Syndrome Market: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Dup15q Syndrome Market Outlook

16. Access and Reimbursement Overview of Dup15q Syndrome

17. KOL Views

18. Dup15q Syndrome Market Drivers

19. Dup15q Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dup15q Syndrome Treatment Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

Biomarkers Industry worth $93.8 billion in 2029, with a CAGR of 10.2%

“Browse 696 market data Tables and 54 Figures spread through 532 Pages and in-depth TOC on “Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Research Area, Technology (NGS, PCR, Mass Spectrometry), Disease (Cancer, Infectious), Application (Diagnostics, Clinical Research) – Global Forecast to 2029”
Biomarkers Market in terms of revenue was estimated to be worth $57.7 billion in 2024 and is poised to reach $93.8 billion by 2029, growing at a CAGR of 10.2% from 2024 to 2029 according to a new report by MarketsandMarkets™.

Biomarkers Market in terms of revenue was estimated to be worth $57.7 billion in 2024 and is poised to reach $93.8 billion by 2029, growing at a CAGR of 10.2% from 2024 to 2029 according to a new report by MarketsandMarkets™.

The growing significance of biomarkers in drug discovery and development, and the growing importance of companion diagnostics are the major driving factors of the biomarkers market. However, high capital investments and lengthy timelines for biomarker development can hamper market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43

The consumables segment accounted for the largest share by product & service segment in the biomarkers market in 2023.

By product & service, the biomarkers market is categorized into consumables, services, and software. The consumables are further sub-segmented into assay kits, reagents & chemicals, columns & filters. The consumables accounted for the largest share of the global biomarkers market in 2023. The large share of consumables is due to the necessity for high-quality products to ensure accurate test results, coupled with the repetitive need for these consumables due to ongoing sample testing in research and clinical settings.

The safety biomarkers segment accounted for the largest share by type segment in the biomarker market in 2023.

By type, the biomarkers market is categorized into safety biomarkers, efficacy biomarkers, and validation biomarkers. The efficacy biomarkers are sub segmented into predictive biomarkers, surrogate biomarkers, pharmacodynamics biomarkers, and prognostic biomarkers. The safety biomarkers segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to their importance in ensuring the safety of pharmaceuticals and healthcare interventions. Safety biomarkers are specifically designed to assess the potential adverse effects, toxicity levels, and safety profiles of drugs and treatments during clinical trials and post-marketing surveillance.

The NGS segment is expected to grow at a higher rate during the forecast period.

Based on technology, the biomarkers market has been segmented into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. The immunoassay technology is sub segmented into ELISA, western blot, and protein microarray. In 2023, the immunoassays segment accounted for the largest share of the biomarkers market, and the NGS segment is expected to grow at a higher growth rate during the forecast period of 2024-2029. The immunoassay segment’s growth is driven by its extensive use in clinical settings for diagnosing diseases, monitoring treatment effectiveness, and predicting patient outcomes.

The cancer segment accounted for the largest share of the disease indication segment in the biomarkers market in 2023.

Based on the disease indication, the biomarkers market is segmented into cancer, infectious diseases, immunological disorders, neurological disorders, cardiovascular disorders, and other disease indications. In 2023, cancer accounted for the largest share of the biomarkers market. The expansion of the cancer biomarkers market is fueled by a surge in research funding dedicated to the rising personalized drug products for cancer treatment.

The North America region accounted for the largest share of the biomarkers market in 2023.

The biomarkers market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. The North America region is witnessing increasing investments and research activities in the field of drug discovery. The need for advanced therapies due to the increased prevalence rate of cancer has contributed to the growth of the biomarkers market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=43

Biomarkers Market Dynamics:

Drivers:

  1. Increase in global prevalence of cancer

Restraints:

  1. Disease complexity and heterogeneity

Opportunities:

  1. Shift towards personalized medicine and precision oncology

Challenge:

  1. Challenges associated with integration of complex data sets

Key Market Players of Biomarkers Industry:

Key players in the biomarkers market F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), Quanterix (US), MESO SCALE DIAGNOSTICS, LLC. (US), EKF Diagnostics (UK), Celerion (US), Standard BioTools (US), Sebia (France), BioAgilytix Labs (US), StressMarq Biosciences Inc. (Canada), NorthEast BioAnalytical Laboratories LLC (US), Signosis, Inc. (US), Serimmune (US), TheraIndx Lifesciences Pvt. Ltd. (India), Synexa Life Sciences BV (Netherlands), Diatech Pharmacogenetics (Italy), Singulex, Inc. (US), R-Biopharm AG (Germany), and Proteome Sciences (UK).

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: C-level Executives – 55%, Director-level – 20%, and Others – 25%
  • By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East -3%, and Africa-2%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=43

Recent Developments of Biomarkers Industry:

  • In January 2024, Quibim and Merck KGaA partnered to develop diagnostic tools to develop the next generation of precision medicine technology targeting a wide range of cancers
  • In October 2023, Quanterix Corporation, a company specializing in ultrasensitive biomarker detection, has announced a new agreement with Johnson & Johnson’s Janssen Sciences Ireland UC to advance blood-based Alzheimer’s disease detection. The agreement grants Quanterix non-exclusive rights to J&J’s p-Tau 217 antibodies and assay designs, enabling the development of a potential Laboratory Developed Test (LDT) for Alzheimer’s Disease (AD) diagnosis and clinical research
  • In February 2023, F. Hoffmann-La Roche Ltd launched two new antibodies to understand a patient’s brain tumor mutation status in the IDH1 and ATRX genes that help in more informed clinical decisions and may improve patient outcomes

Biomarkers Market – Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Growing significance of biomarkers in drug discovery and development, Growing importance of companion diagnostics, Increase in global prevalence of cancer, Growing importance of biomarkers for rare conditions, Increase in funds and grants for biomarker research, Advancement in omics technologies and continuous product innovations), restraints (High capital investments and lengthy timelines for biomarker development, Disease complexity, and heterogeneity), opportunities (Shift towards personalized medicine and precision oncology, Enhanced collaboration among healthcare providers and key industry players, Emerging economies), and challenges (Challenges associated with quantification and validation of biomarkers, Challenges associated integration of complex data sets, Technical issues related to sample collection and storage) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on newly launched products/services of the biomarkers market
  • Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the biomarkers market
  • Competitive Assessment: F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMÉRIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), Quanterix (US), MESO SCALE DIAGNOSTICS, LLC. (US), EKF Diagnostics (UK), Celerion (US), Standard BioTools (US), Sebia (France), BioAgilytix Labs (US), StressMarq Biosciences Inc. (Canada), NorthEast BioAnalytical Laboratories LLC (US), Signosis, Inc. (US), Serimmune (US), TheraIndx Lifesciences Pvt. Ltd. (India), Synexa Life Sciences BV (Netherlands), Diatech Pharmacog

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/biomarkers-advanced-technologies-and-global-market-43.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biomarkers Industry worth $93.8 billion in 2029, with a CAGR of 10.2%

VirtusX Unveils the Jethro V1 AI Mouse, an Innovative New AI Assistant Featuring ChatGPT

This carefully crafted mouse is the ultimate AI assistant, featuring ChatGPT capabilities for voice and text language translation, voice typing, creating PowerPoints, and much more

The VirtusX team is excited to introduce the Jethro V1 AI Mouse—an innovative assistant powered by OpenAI’s ChatGPT technology. Enjoy this cutting-edge AI mouse with no subscription fees, exclusively for Kickstarter VIPs, normally priced at $99/year.

IDAP research indicates that nearly 97% of mobile users are leveraging AI-powered voice assistants for both professional and personal purposes. While Siri, Alexa, and Google Assistant have gained widespread popularity, they primarily function on mobile phones and tablets, leaving a gap for computer and laptop users.

VirtusX is committed to harnessing AI for the greater good, and with the recent unveiling of its flagship Jethro V1 AI Mouse, users will soon have access to a groundbreaking, first-of-its-kind AI mouse. This innovative device features an embedded microphone and integrates advanced AI technology, transforming daily life by significantly enhancing productivity and efficiency. Get ready to elevate your computing experience with the Jethro V1 AI Mouse!

The VirtusX Jethro V1 AI Mouse is sleek, streamlined, and smartly crafted. Designed for daily use, this Bluetooth mouse seamlessly connects with laptops and desktops for simple and convenient use. While it functions as a classic mouse, the Jethro V1 AI Mouse is unlike any other peripheral device on the market today. It features powerful OpenAI ChatGPT software that yields the ultimate productivity tool. When people use the Jethro V1 AI Mouse, they have the most advanced AI assistant in the palm of their hand. “Imagine having ChatGPT available on-demand as you’re working, playing game, or surfing the web,” said a spokesperson for VirtusX. “That’s what our new Jethro V1 AI Mouse has to offer.”

To be specific, this groundbreaking new device features an AI Smart Toolbar that offers an on-screen presence that coordinates the user experience for seamless one-click translation, rewriting, expanding, shortening, and summarizing text. People can leverage the Jethro V1 AI Mouse for PowerPoint generation, image creation, and voice typing and translation in more than 100 languages. The built-in OCR and document reader allows the Jethro V1 AI Mouse to summarize any document in mere seconds, and voice-to-text makes writing papers and e-mails easier than ever.

The VirtusX Jethro V1 AI Mouse was designed with ease of use in mind and is controlled via 3 pre-built AI buttons and a built-in microphone. There are no accounts or subscriptions required to use this mouse, which is the perfect addition to the home or office of anyone who can benefit from AI chatbots, writing tools, rewriting tools, image generation, summarization, and PowerPoint creation assistance. The Jethro V1 AI Mouse features a 400mAh lithium ion battery that will serve users for up to 30 days on a single charge.

According to the team at VirtusX, the Jethro V1 AI Mouse will soon be launching on Kickstarter. When it makes its debut, people everywhere will have an opportunity to pledge to the launch of the mouse while getting exclusive perks in return. Stay up to date by visiting https://www.kickstarter.com/projects/908005844/jethro-v1-ultimate-chatgpt-powered-ai-mouse .

ABOUT VIRTUSX

VirtusX creates appealing desk setups and streamlined workspace ideas that inspire and transform environments. 

Media Contact
Company Name: VirtusX
Contact Person: Jerry Hsu
Email: Send Email
Country: United States
Website: https://aimousejethro.virtusxus.com/

Julianna Newland’s New Book “All Up In Your Bizness: Managing Your Business Crap” Out Now

“All Up In Your Bizness: Managing Your Business Crap” is an empowering offbeat guide to mastering office life. The book offers witty yet insightful tips.

Recent release, “All Up In Your Bizness: Managing Your Business Crap” by Julianna Newland, is shaking up the traditional office handbook with a lighthearted, refreshingly candid approach to workplace courtesy and customs. The new book features practical and useful advice for modern workers as they navigate their 9-to-5 routines.

Described as “a smart, funny, and useful overview of how to behave at work” on Kirkus Reviews, “All Up In Your Bizness” is a witty, no-nonsense guide that combines humor with relatable anecdotes and practical advice for surviving in today’s work environment. Newland writes about the spoken and unspoken etiquettes of the workplace to help readers navigate workplace dynamics and the complexities of office etiquette. Through this book, she equips readers with the tools to navigate everything from awkward meetings to workplace gossip.

Newland’s engaging writing style shines in this offbeat guide to mastering office life. Her real-world solutions, wrapped in laugh-out-loud commentary, offer a much-needed guide to dealing with other people at work and in life. She goes from advising people against deluding themselves into thinking they are more important than the boss’s secretary to detailing the importance of taking the exit interview process very seriously.

“All Up In Your Bizness: Managing Your Business Crap” is a must-read for both workforce newcomers and seasoned employees. The book features digestible tips outlined in bulleted points and humorous cartoons, representing a serious yet light approach that gets the point across. The book will debut at the 2024 Brooklyn Book Festival in New York this September 22-30. Newland invites professionals to find within the pages of this workplace handbook the key to mastering office courtesy and customs without losing their sense of humor.

“All Up In Your Bizness: Managing Your Business Crap” is now available on Amazon and other leading online publishers. Grab a copy today. Also, catch Newland and her witty take on business etiquette at the 2024 Brooklyn Book Festival in New York for more of her truth through laughter.

Media Contact
Company Name: All Up In Your Bizness: Managing Your Business Crap
Contact Person: Julianna Newland
Email: Send Email
Country: United States
Website: https://juliannanewland.org/

Seasonal Influenza Treatment Market Size in the 7MM was ~USD 9177 million in 2023, estimated DelveInsight

Seasonal Influenza Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Seasonal Influenza Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Seasonal Influenza Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Seasonal Influenza, historical and forecasted epidemiology as well as the Seasonal Influenza market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Seasonal Influenza Market by downloading the comprehensive report from DelveInsight @ Seasonal Influenza Treatment Market Size

 

Key Takeaways from the Seasonal Influenza Market Report

  • In September 2024:- ModernaTX Inc.- A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared With a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age. The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains.
  • In 2023, as per DelveInsight’s assessment, 37 million medical visits related to seasonal influenza were estimated in the 7MM. These cases are projected to rise by 2034 at a CAGR of 0.3%.
  • In the EU4 and UK , in 2023, Italy had the highest medical visits related to seasonal influenza with 5  million cases, followed by Germany with 4 million cases in the same year. On the other hand, Spain had the lowest medical visits of seasonal influenza as 833 thousand cases in 2023.
  • The leading Seasonal Influenza Companies such as SAb Biotherapeutics, Inc., Emergo Therapeutics, Inc., AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, Inc., NanoViricides, Evrys Bio, ETHRIS, Kino Pharma, and others.
  • Promising Seasonal Influenza Therapies such as mRNA-1010, SAB-176, TETRALITE, mRNA-1345, and others.

 

Gain a competitive edge in the Seasonal Influenza Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Seasonal Influenza Treatment Drugs

 

Seasonal Influenza Epidemiology Segmentation in the 7MM

  • Total Medical visits related to Seasonal Influenza
  • Total Seasonal Influenza Hospitalized Cases
  • Seasonal Influenza Type-specific Cases
  • Seasonal Influenza Vaccination

 

Seasonal Influenza Market Insights

Seasonal Influenza spreads through respiratory droplets and is very contagious, and most people can receive at- home care for the flu. Symptom relief may be achieved by combining lifestyle changes with over-the-counter medications. Patients not from a high-risk group can be managed with symptomatic treatment whereas, patients with severe or progressive clinical illness associated with suspected or confirmed influenza virus infection (i.e., clinical syndromes of pneumonia, sepsis, or exacerbation of chronic underlying diseases) can be treated with the antiviral drug. Prophylactic treatment is part of the treatment for influenza.

 

Discover key developments and opportunities in the Seasonal Influenza Market. Click here to learn more from DelveInsight’s latest report @ Seasonal Influenza Market Size

 

Seasonal Influenza Marketed Therapies

  • XOFLUZA (baloxavir marboxil): Genentech/Roche

XOFLUZA is a first-in-class, single-dose oral medicine with an innovative proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies.

 

  • FLUZONE QUADRIVALENT /VAXIGRIP TETRA: Sanofi

FLUZONE QUADRIVALENT is a quadrivalent inactivated influenza vaccine produced in the US, containing two Type A antigens and two Type B antigens to provide increased protection against more circulating strains of influenza viruses.

 

Seasonal Influenza Emerging Therapies

  • SAB-176: SAb Biotherapeutics, Inc.

SAB-176 is a multivalent, broadly neutralizing fully human polyclonal antibody therapeutic candidate developed by SAb Biotherapeutics that leverages the human biological immune response in developing the treatment of hospitalized patients with severe seasonal influenza.

 

Seasonal Influenza Emerging Vaccines

  • mRNA-1010: ModernaTX, Inc.

mRNA-1010 is Moderna’s first seasonal influenza mRNA vaccine candidate to enter the clinic. The mRNA-1010 is a quadrivalent vaccine candidate that encodes for hemagglutinin glycoproteins of the four influenza strains recommended by the WHO for the prevention of influenza, including influenza A/H1N1, A/H3N2, and Influenza B/Yamagata- and B/Victoria-lineages.is Moderna’s first seasonal influenza mRNA vaccine candidate to enter the clinic.

 

Seasonal Influenza Market Outlook

Seasonal Influenza spreads through respiratory droplets and is very contagious, and most people can receive at-home care for the flu. Symptom relief may be achieved by combining lifestyle changes with over-the-counter medications. Patients not from a high-risk group can be managed with symptomatic treatment whereas, patients with severe or progressive clinical illness associated with suspected or confirmed influenza virus infection (i.e., clinical syndromes of pneumonia, sepsis, or exacerbation of chronic underlying diseases) can be treated with the antiviral drug. Prophylactic treatment is part of the treatment for influenza.

 

Download DelveInsight’s Seasonal Influenza Market report today and stay ahead in this rapidly evolving field. @ Seasonal Influenza Clinical Trials

 

Scope of the Seasonal Influenza Market Report

  • Coverage- 7MM
  • Seasonal Influenza Companies- SAb Biotherapeutics, Inc., Emergo Therapeutics, Inc., AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, Inc., NanoViricides, Evrys Bio, ETHRIS, Kino Pharma, and others.
  • Seasonal Influenza Therapies- mRNA-1010, SAB-176, TETRALITE, mRNA-1345, and others.
  • Seasonal Influenza Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Seasonal Influenza Unmet Needs, KOL’s views, Analyst’s views, Seasonal Influenza Market Access and Reimbursement

 

Download the report to understand which factors are driving Seasonal Influenza Market Trends @ Seasonal Influenza Market Trends

 

Table of Content

1. Key Insights

2. Report Introduction

3. Seasonal Influenza Market Overview at a Glance

4. Seasonal Influenza Market: Future Perspective

5. Executive Summary of Seasonal Influenza

6. Key Events

7. Disease Background and Overview: Seasonal Influenza

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Drugs

11. Marketed Vaccines

12. Comparative Analysis

13. Emerging Therapies

14. Emerging Vaccines and Prophylactic Agents

15 Seasonal Influenza: Seven Major Market Analysis

16. Key Opinion Leaders’ Views

17. Seasonal Influenza Market Drivers

18. Seasonal Influenza Market Barriers

19. Seasonal Influenza Market Unmet Needs

20. SWOT Analysis

21. Market Access and Reimbursement

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Seasonal Influenza Treatment Market Size in the 7MM was ~USD 9177 million in 2023, estimated DelveInsight

Infectious Disease Diagnostics Market Forecast to Grow at 8.20% CAGR from 2024 to 2031 | SkyQuest Technology

“Infectious Disease Diagnostics Market”
Global Infectious Disease Diagnostics Market size was valued at USD 22.94 billion in 2023 to USD 43.09 billion by  2031, growing at a CAGR of 8.20% during the forecast period (2024-2031).

 Global Infectious Disease Diagnostics Market size was valued at USD 21.20 billion in 2022 and is poised to grow from USD 22.94 billion in 2023 to USD 43.09 billion by  2031, growing at a CAGR of 8.20% during the forecast period (2024-2031).

Increasing incidence of infectious diseases, shift of emphasis from centralized laboratories to center of care, increasing R&D activity in infectious disease diagnostics are other factors leading to market expansion. Point-of-care diagnosis provides rapid and useful information for patient care at the point of diagnosis. Consequently, many companies have focused R&D programs to develop point-of-care diagnostic solutions for developing countries. Leading companies are constantly innovating their products through the introduction of new products, joint ventures with third parties, mergers and acquisitions, all of which will contribute to the expansion of the global market. 

The infectious diseases diagnostics market is growing rapidly due to increasing prevalence of infectious diseases, increasing sophistication of diagnostic tools and advancements in molecular diagnostics. The competitive scenario of this market can be classified based on players, their strategies, technological developments and collaboration. 

 

Get a Free Sample Research Report:

https://www.skyquestt.com/sample-request/infectious-disease-diagnostics-market

 

Infectious Disease Diagnostics Market Segmental Analysis

Global Infectious Disease Diagnostics Market is segmented by Product & Service, Type of Testing, Sample Type, Disease Type, Technology, End User, and region. 

Based on Product & Service, the market is segmented into Reagents, Kits, And Consumables, Instruments, Software & Services. 

Based on Type of Testing, the market is segmented into Laboratory Testing, POC Testing. Based on Sample Type, the market is segmented into Blood, Serum, and Plasma, Urine, and Other Sample Types. 

Based on Disease Type, the market is segmented into Hepatitis, HIV, Hospital-acquired Infections, Mosquito-borne Diseases, HPV, Chlamydia Trachomatis, Neisseria Gonorrhea, Tuberculosis, Influenza, Syphilis, Other Infectious Diseases. 

Based on Technology, the market is segmented into Immunodiagnostics, Clinical Microbiology, Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing & Next-generation Sequencing, DNA Microarray, Other Technologies. 

Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, Academic Research Institutes, Other End Users. 

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

 

Diagnostics at the Forefront Navigating the Competitive Landscape of Infectious Disease Detection

Large, established companies dominate market for the infectious disease testing, leveraging their global reach, advanced R&D capabilities, and portfolios. Companies such as Roche Diagnostics, Abbott Laboratories, bioMérieux, Becton Dickinson (BD) leads the market with a focus on the delivering innovative diagnostic solutions Invests heavily in technology integration and development.

Roche Diagnostics is distinguished by a strong portfolio of molecular diagnostics, particularly real-time PCR systems that are a key component in the detection of infectious disease. The company’s COBAS diagnostic system plays a critical role in its market dominance.

Abbott Laboratories is focused on point-of-care testing, offering rapid diagnostic solutions such as ID NOW™ which is widely used to rapidly identify viruses such as SARS-CoV-2.

 

This report covers the following players:

  • F. Hoffmann-La Roche Ltd. (Switzerland) 
  • Abbott (US) 
  • bioMérieux (France) 
  • Siemens Healthineers AG (Germany) 
  • Danaher (US) 
  • Thermo Fisher Scientific Inc. (US) 
  • Hologic, Inc. (US) 
  • Becton, Dickinson and Company (US) 
  • Revvity (US) 
  • Qiagen (Netherlands) 
  • Seegene Inc. (South Korea) 
  • QuidelOrtho Corporation (US) 
  • Grifols, S.A. (Spain) 
  • DiaSorin S.p.A. (Italy) 
  • Bio-Rad Laboratories, Inc. (US) 
  • Sysmex Corporation (Japan) 
  • OraSure Technologies (US) 
  • Co-Diagnostics, Inc. (US) 
  • Trinity Biotech (Ireland) 
  • Genetic Signatures Ltd. (Australia) 
  • Epitope Diagnostics, Inc. (US) 
  • Trivitron Healthcare (India) 
  • ELITech Group (France) 
  • Meril Life Sciences Pvt. Ltd. (India)
  • InBios International, Inc. (US) 
  • Uniogen Oy (Finland) 
  • Vela Diagnostics (Singapore)

 

Ask for Customization:

https://www.skyquestt.com/speak-with-analyst/infectious-disease-diagnostics-market

 

Strategic Cooperation and Partnership

In May 2022, The U.S. Food and Drug Administration (FDA) has granted Abbott emergency use authorization (EUA) for the fastest available molecular point-of-care test for the detection of new coronavirus (COVID-19), which provides positive findings in as little as five minutes and negative results in 13 minutes.

In May 2022, Quidel Corporation a US-based organization that provides rapid diagnostic testing solutions, cellular-based totally virology assays, and molecular diagnostic systems, has received Ortho Clinical Diagnostics and the succeeding enterprise corporations.

 

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/infectious-disease-diagnostics-market

 

This report covers the following segments:

A. Product & Service

  1. Software & Services
  2. Instruments

B.  Type of Testing 

  1. Laboratory Testing
  2. POC Testing

C. Sample Type

  1. Blood
  2. Serum
  3. Plasma
  4. Urine

C. Disease Type

  1. Hepatitis
  2. Mosquito-borne Diseases

 

Empowering Global Health of Infectious Disease Diagnostics Market

The infectious disease diagnostics market is poised for strong growth, driven by the rising incidence of infectious diseases across the globe, including emerging pathogens such as COVID-19 and drug resistance. Companies are responding with innovations in molecular testing, point-of-care testing and rapid diagnostic tools to meet the growing demand for accurate, rapid discovery. The future of this market depends on the next technologies such as AI-enhanced diagnostic platforms, CRISPR-based detection tools, and advanced molecular diagnostic techniques. 

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/infectious-disease-diagnostics-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Infectious Disease Diagnostics Market Forecast to Grow at 8.20% CAGR from 2024 to 2031 | SkyQuest Technology

The Body Contouring Devices Market to Hit $15.21 Billion by 2029, More than $9 Billion Opportunities for Industry Players – Arizton

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

 

According to Arizton’s latest research report, the global body contouring devices market is growing at a CAGR of 14.14% during 2023-2029.

       

Looking for More Information? Click: https://www.arizton.com/market-reports/body-contouring-devices-market

  

Report Scope:       

Market Size (2029): USD 15.21 Billion   

Market Size (2023): USD 6.88 Billion  

CAGR (2023-2029): 14.14%  

Historic Year: 2020-2023   

Base Year: 2023    

Forecast Year: 2024-2029  

Market Segmentation: Procedure, Gender, Application, Age Group, End-User, and Geography

Geographic Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa 

      

Book the Free Sample Now: https://www.arizton.com/market-reports/body-contouring-devices-market

 

The global body contouring devices market report highlights exclusive data on 37 vendors, illustrating a highly competitive landscape with numerous global, regional, and local players offering a variety of devices. These devices are used for skin tightening, cellulite treatment, and muscle toning. Intense competition is driven by technological advancements and the rising demand for minimally invasive procedures. Leading companies, including AbbVie, Bausch Health Companies, Cutera, Shanghai Fosun Pharmaceutical, and Hologic, are strategically expanding into the Asia-Pacific (APAC) and Middle Eastern markets. This expansion is motivated by increasing awareness and adoption of skin tightening and other body contouring treatments in these regions, creating significant growth opportunities for global players in emerging markets.

 

Non-Surgical Skin Tightening the Fastest Growing Segment With A CAGR Of 14.84%

Non-surgical fat elimination and skin tightening procedures are becoming increasingly popular, driven by the aging population and the common issue of sagging skin. As individuals age, particularly between 35 and 40, natural declines in collagen, hyaluronic acid, and elastin create a heightened demand for skin tightening solutions.

Laser-based devices dominate this market due to their effectiveness across all skin types and low risk of damage. Companies like Fotona offer innovative treatments such as TightSculpting and Fotona4D. Radiofrequency (RF) devices, like Cynosure’s TempSure Envi, have become popular alternatives, particularly for darker skin tones.

The rising interest in skin tightening is also reflected in cosmetic surgeries, including buttock lifts and thigh lifts, which have seen significant increases in procedures. In 2023, there were about 110,167 buttock lifts, up from 95,174 in 2022.

Overall, the aging population and increased skin loosening have spurred growth in non-surgical and surgical skin tightening procedures. As technology advances, the market for effective, minimally invasive options is expected to continue expanding.

 

Key Vendors

  • AbbVie
  • Bausch Health Companies
  • Cutera
  • Shanghai Fosun Pharmaceutical
  • Hologic
  • Aerolase
  • Asclepion Laser Technologies
  • Beijing ADSS Development
  • Biolitec
  • Biotec Italia
  • BISON Medical
  • Brera Medical Technologies
  • BTL Aesthetics
  • Cartessa
  • Candela
  • Deleo
  • El.En. S.p.A.
  • Dominion Aesthetic Technologies
  • ENDYMED
  • Erchonia
  • F Care Systems
  • Fotona
  • GSD
  • InMode Aesthetic Solutions
  • Lutronic
  • Lumenis
  • Lynton Lasers
  • Leaflife Technology
  • MedArt ApS
  • Microaire Surgical Instruments
  • Merz Aesthetics
  • PhotoMedex
  • Sciton
  • Sofwave
  • ThermiGen
  • Venus Concept
  • Wavemed

 

Segmentation & Forecast

 

Procedure

  • Non-invasive
  • Minimally invasive

 

Age Group

  • Between 34-50 Years
  • Above 50 Years
  • Below 34 Years

 

Gender

  • Female
  • Male

 

Application

  • Non-surgical Skin Tightening
  • Non-surgical Skin Resurfacing
  • Liposuction
  • Cellulite Reduction
  • Others

 

End-User

  • Hospitals
  • Medical Spa & Beauty Centers
  • Specialty Skincare Clinics
  • Individuals

 

Geography

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • Italy
  • Russia
  • Spain
  • France
  • The UK
  • APAC
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • The UAE
  • South Africa
  • Saudi Arabia
  • Turkey

  

In a nutshell, the Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to understand the body contouring devices market thoroughly. Request for Free Sample to get a glance at the report now: https://www.arizton.com/market-reports/body-contouring-devices-market

     

What Key Findings Will Our Research Analysis Reveal?     

How big is the global body contouring devices market?

What is the growth rate of the global body contouring devices market?

What are the key drivers of the global body contouring devices market?

Which region dominates the global body contouring devices market?

Who are the major players in the global body contouring devices market?

     

Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4504

     

Other Related Reports that Might be of Your Business Requirement     

Indonesia Medical Aesthetics Market – Focused Insights 2024-2029: The Indonesia medical aesthetics market was valued at USD 257.05 million in 2023 and is expected to reach USD 495.64 million by 2029, growing at a CAGR of 11.56% during the forecast period. Explore! https://www.arizton.com/market-reports/indonesia-medical-aesthetics-market

Global Medical Aesthetics Market – Focused Insights 2024-2029: The global medical aesthetics market was valued at USD 21.03 billion in 2023 and is expected to reach USD 39.87 billion by 2029, growing at a CAGR of 11.25% during the forecast period. Explore! https://www.arizton.com/market-reports/medical-aesthetics-market

  

Why Arizton?                                                

100% Customer Satisfaction                                                

24×7 availability – we are always there when you need us                                                

200+ Fortune 500 Companies trust Arizton’s report                                                

80% of our reports are exclusive and first in the industry                                                

100% more data and analysis                                                

1500+ reports published till date                              

                   

Post-Purchase Benefit                                            

  • 1hr of free analyst discussion                                            
  • 10% off on customization                         

                  

About Us:                                                                                     

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                                   

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                                    

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                                          

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707                                    
Country: United States
Website: https://www.arizton.com/market-reports/body-contouring-devices-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Body Contouring Devices Market to Hit $15.21 Billion by 2029, More than $9 Billion Opportunities for Industry Players – Arizton